Glaucoma Treatment Cost: Eye Drops, Laser & Surgery Options

More than 3 million Americans have glaucoma — and about half of them don’t know it. The National Eye Institute (NEI) reports that glaucoma is the leading cause of irreversible blindness in the United States, responsible for roughly 120,000 cases of legal blindness annually. What makes that number alarming: by the time you notice vision loss, significant optic nerve damage has already happened. Glaucoma is called “the silent thief of sight” because it steals peripheral vision so gradually that most people adapt without realizing what’s gone.

Once diagnosed, treatment is lifelong. There’s no finish line. And the costs span an enormous range — from $15/month for a generic eye drop to $10,000+ for a single surgical procedure. Here’s where you’re likely to land on that spectrum, and why.

The Treatment Ladder: From Drops to Surgery

Glaucoma treatment follows a step-therapy approach. You start with the least invasive option that adequately controls your intraocular pressure (IOP), and escalate if that fails or becomes intolerable. The AAO’s Preferred Practice Pattern for primary open-angle glaucoma outlines this framework — drops first, laser as a viable alternative, surgery for refractory cases.

For most newly diagnosed patients, treatment starts with a generic prostaglandin analog — latanoprost, travoprost, or bimatoprost. Generic latanoprost runs about $15–$30/month through GoodRx at major pharmacies. That’s $180–$360/year. It’s a once-daily drop, it works well, and it’s the cheapest effective option in glaucoma treatment. Timolol (a beta-blocker) and brimonidine (an alpha-agonist) are common add-ons when a second agent is needed, each adding $10–$40/month.

The math changes fast when brand-name drops enter the picture. Xalatan — the brand-name version of latanoprost — runs $180–$220/month, roughly 8x the generic cost. Unless there’s a specific reason your doctor is prescribing brand, there generally isn’t a clinical advantage over generic latanoprost for most patients.

Laser Trabeculoplasty (SLT): The First-Line Alternative

The landmark LiGHT trial, published in The Lancet in 2019, changed how ophthalmologists think about first-line glaucoma care. It found that selective laser trabeculoplasty (SLT) achieved equivalent IOP control to drops for 74% of patients over 3 years — and those patients had better quality-of-life scores because they weren’t taking daily drops. The AAO now recognizes SLT as an appropriate first-line option, not just a step-up from failing drops.

SLT costs $1,000–$1,800 per eye as a standalone procedure. It’s covered by Medicare Part B at 80% after deductible — meaning most Medicare patients pay $200–$360 per eye. Most commercial insurers cover it when medically indicated. Effects typically last 3–5 years, and the procedure is repeatable.

Minimally Invasive Glaucoma Surgery (MIGS)

MIGS represents a newer category of surgical options designed to lower IOP with less risk and faster recovery than traditional glaucoma surgery. Procedures like iStent, Hydrus microstent, and GATT (gonioscopy-assisted transluminal trabeculotomy) are most commonly performed in combination with cataract surgery, where they add relatively little incremental cost to an already-planned procedure.

As standalone procedures, MIGS runs $1,500–$5,000 per eye. Insurance coverage is generally available for patients who meet medical necessity criteria — typically moderate-to-advanced glaucoma not adequately controlled with drops. The tradeoff compared to traditional surgery: less pressure reduction, but also less risk of complications like hypotony or infection.

Traditional Surgery: Trabeculectomy and Tube Shunts

When drops and laser fail, two traditional surgical approaches remain the gold standard for advanced glaucoma.

Trabeculectomy creates a surgical drainage pathway — a filtration bleb — under the conjunctiva to drain aqueous humor and lower pressure. It’s the most established glaucoma surgery, with decades of outcomes data. Procedure cost: $3,000–$6,000/eye for the combined surgeon fee, facility, and anesthesia, before insurance. Medicare typically covers 80% after deductible.

Tube shunts (Baerveldt, Ahmed) implant a drainage tube and reservoir plate that diverts aqueous humor. They’re increasingly used in eyes where trabeculectomy has failed or is high-risk. Cost: $5,000–$10,000/eye before insurance.

Ongoing Monitoring Costs

Glaucoma isn’t just treated — it’s monitored. Every 6–12 months, you’ll need:

• Visual field testing ($75–$200/test): Maps peripheral vision loss and tracks progression. Medicare covers this at 80% for diagnosed glaucoma patients.
• OCT optic nerve scan ($75–$150): Measures retinal nerve fiber layer thickness — the earliest sign of progressive damage. Also covered by Medicare at 80%.
• IOP measurement at each visit: Included in office visit cost.

Annual monitoring adds $300–$700/year in testing costs even with stable, well-controlled disease. Over a lifetime, it’s a real number — but it’s the number that catches progression early enough to escalate treatment before more vision is lost.

Medicare Coverage Summary

Medicare Part B is the main coverage vehicle for glaucoma, not your vision plan. Part B covers:

• Glaucoma screenings for high-risk individuals (80% after deductible)
• Diagnostic testing — visual fields, OCT (80% after deductible)
• SLT laser treatment (80% after deductible)
• Surgical procedures (80% after deductible)

Eye drops go through Medicare Part D. Generic drugs are typically Tier 1 (lowest cost sharing); brand-name drops may require step therapy with generics first.

Medigap plans F and G cover the 20% Part B coinsurance — on a $6,000 trabeculectomy, that’s $1,200 in patient share that Medigap eliminates. If you have glaucoma and are on Medicare, checking your Medigap coverage specifically for surgical coinsurance is worth the effort.